Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran
- 1 March 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 18 (2), e29-e34
- https://doi.org/10.1097/mjt.0b013e3181c0806d
Abstract
Compared with the treatment of drug-sensitive tuberculosis, the treatment of multidrug-resistant tuberculosis (MDR-TB) is more difficult. This study was conducted at the national referral center of tuberculosis in Tehran, Iran, to evaluate adverse drug reactions of treatment of MDR-TB. From 2006 to 2009, all patients admitted into Masih Daneshvari Hospital in Tehran, Iran, for MDR-TB were considered for this study. The standard treatment for MDR-TB consisted of amikacin, prothionamide, ofloxacin, and cycloserine. Ethambutol and pyrazinamide were added to treatment if mycobacterium was sensitive to them. All adverse effects observed in patients were recorded in our registry. Eighty patients were considered in the study; of this cohort, 44 were male and 36 were female. The mean age of patients was 40.64 ± 17.53 years (range, 14-81 years). All patients received standardized therapy for MDR-TB. The major adverse effects included neurologic side effects (depression, convulsions, consciousness, psychosis, suicide; 7.5%), hepatitis (5%), rash (1.3%), renal toxicity (3.8%), and auditory toxicity (14.5%). Those with neurologic side effects had less favorable outcome (P value = 0.038) and risk of death was increased among them (odds ratio, 13.8; 95% confidence interval, 2.2-86.77). Other adverse effects did not show statistical significance in our analysis. A major adverse effect such as neurologic side effects (depression, convulsions, consciousness, and psychosis) can result in an increased chance of death among patients with MDR-TB.Keywords
This publication has 15 references indexed in Scilit:
- Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive studyScandinavian Journal of Infectious Diseases, 2009
- Management of multidrug-resistant tuberculosis in the Asia-Pacific regionRespirology, 2008
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort studyThe Lancet, 2005
- Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Programmes and principles in treatment of multidrug-resistant tuberculosisThe Lancet, 2004
- Current medical treatment for tuberculosisBMJ, 2002
- Multidrug-resistant tuberculosisInfectious Disease Clinics of North America, 2002
- Frequency and type of reactions to antituberculosis drugs: Observations in routine treatmentTubercle and Lung Disease, 1996
- Surgical Intervention in the Treatment of Pulmonary Disease Caused by Drug-resistantMycobacterium tuberculosisAmerican Review of Respiratory Disease, 1990